Literature DB >> 26207166

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.

Vikas Khullar1, Roberto J Firpi1.   

Abstract

Chronic hepatitis C infection is the leading cause of chronic liver disease, cirrhosis, hepatocellular carcinoma as well as the primary indication for liver transplantation in the United States. Despite recent advances in drugs for the treatment of hepatitis C, predictive models estimate the incidence of cirrhosis due to hepatitis C infection will to continue to rise for the next two decades. There is currently an immense interest in the treatment of patients with fibrosis and early-stage cirrhosis as treatment can lead to decrease in the rates of decompensated cirrhosis, hepatocellular carcinoma and need for liver transplantation in these patients. The goal of this paper is to provide clinicians and health care professionals further information about the treatment of patients with hepatitis C infection and cirrhosis. Additionally, the paper focuses on the disease burden, epidemiology, diagnosis and the disease course from infection to treatment. We provide an overview of multiple studies for the treatment of chronic hepatitis C infection that have included patients with cirrhosis. We also discuss the advantages and disadvantages of treatment in cirrhotic patients and focus on the most up to date guidelines available for treatment.

Entities:  

Keywords:  Cirrhosis; Diagnosis; Hepatitis C virus; Ledipasvir; Liver transplantation; Simeprevir; Sofosbuvir; Treatment

Year:  2015        PMID: 26207166      PMCID: PMC4506942          DOI: 10.4254/wjh.v7.i14.1843

Source DB:  PubMed          Journal:  World J Hepatol


  60 in total

1.  Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.

Authors:  Nicola Coppola; Stefania De Pascalis; Mariantonietta Pisaturo; Laurenza Paradiso; Margherita Macera; Nicolina Capoluongo; Loredana Alessio; Maria Stanzione; Caterina Sagnelli; Carmine Minichini; Evangelista Sagnelli
Journal:  J Clin Virol       Date:  2013-09-23       Impact factor: 3.168

Review 2.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

3.  A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.

Authors:  Gregory T Everson; Norah A Terrault; Anna S Lok; Del R Rodrigo; Robert S Brown; Sammy Saab; Mitchell L Shiffman; Abdullah M S Al-Osaimi; Laura M Kulik; Brenda W Gillespie; James E Everhart
Journal:  Hepatology       Date:  2013-01-17       Impact factor: 17.425

4.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

5.  Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies.

Authors:  Jianmeng Chen; Jeffry Florian; Wendy Carter; Russell D Fleischer; Thomas S Hammerstrom; Pravin R Jadhav; Wen Zeng; Jeffrey Murray; Debra Birnkrant
Journal:  Gastroenterology       Date:  2013-03-05       Impact factor: 22.682

6.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

9.  PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.

Authors:  Angela M Lam; Eisuke Murakami; Christine Espiritu; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Veronique Zennou; Nigel Bourne; Justin G Julander; John D Morrey; Donald F Smee; David N Frick; Julie A Heck; Peiyuan Wang; Dhanapalan Nagarathnam; Bruce S Ross; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  12 in total

1.  Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.

Authors:  Stacey B Prenner; Lisa B VanWagner; Steven L Flamm; Riad Salem; Robert J Lewandowski; Laura Kulik
Journal:  J Hepatol       Date:  2017-02-02       Impact factor: 25.083

2.  Serum amyloid a induces M2b-like macrophage polarization during liver inflammation.

Authors:  Yibin Wang; Haijun Huang; Renhua Sun; Bingyu Chen; Fang Han; Qian Li; Yin Ni; Xi Li; Jingquan Liu; Xiaozhou Mou; Yuexing Tu
Journal:  Oncotarget       Date:  2017-11-23

3.  Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c.

Authors:  Tien S Dong; Elizabeth S Aby; Jihane N Benhammou; Jenna Kawamoto; Steven-Huy Han; Folasade P May; Joseph R Pisegna
Journal:  World J Hepatol       Date:  2018-09-27

Review 4.  Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis.

Authors:  Hung-Chang Hung; Hsien-Hua Liao; Shiuan-Chih Chen; Shih-Ming Tsao; Yuan-Ti Lee
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.

Authors:  Eric Lawitz; Fred Poordad; Julio A Gutierrez; Maria Beumont; Greet Beets; Ann Vandevoorde; Pieter Van Remoortere; Donghan Luo; Leen Vijgen; Veerle Van Eygen; Mohamed Gamil
Journal:  Health Sci Rep       Date:  2020-02-22

6.  The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands.

Authors:  Mohamed N M T Al Khayat; Job F H Eijsink; Maarten J Postma; Jan C Wilschut; Marinus van Hulst
Journal:  Int J Environ Res Public Health       Date:  2020-08-21       Impact factor: 3.390

7.  Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center.

Authors:  Omar T Sims; Duong N Truong; Kaiying Wang; Pamela A Melton; Kasey Atim
Journal:  J Racial Ethn Health Disparities       Date:  2021-07-12

8.  The Etiology, Incidence, and Impact of Preservation Fluid Contamination during Liver Transplantation.

Authors:  Isabel Oriol; Laura Lladó; Marina Vila; Carme Baliellas; Fe Tubau; Núria Sabé; Joan Fabregat; Jordi Carratalà
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

9.  Sofosbuvir and daclatasvir.

Authors:  Marleen H M Hessel; Adam F Cohen; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2016-06-12       Impact factor: 4.335

10.  The Initiation Factors eIF2, eIF2A, eIF2D, eIF4A, and eIF4G Are Not Involved in Translation Driven by Hepatitis C Virus IRES in Human Cells.

Authors:  Esther González-Almela; Hugh Williams; Miguel A Sanz; Luis Carrasco
Journal:  Front Microbiol       Date:  2018-02-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.